DeFronzo 2009

NCT00121667

1 Treatments

Studied treatment  saxagliptin (2.5, 5, or 10 mg once daily)

Control treatment  placebo

Concomittant treatments  stable dose of metformin (1,500-2,500 mg)

2 Patients

Patients  Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

Inclusion criteria  (A1C ≥7.0 and ≤10.0%)

Exclusion criteria  -

3 Methods

Blinding  -

Design  -

Centers  -

Geographical area  -

Sizes  191/179

4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>stroke</td>
<td>-/191</td>
<td>-/179</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>HbA1c goal &lt;7 all cause deaths</td>
<td>-/191</td>
<td>-/179</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>nephropathy</td>
<td>-/191</td>
<td>-/179</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV events</td>
<td>-/191</td>
<td>-/179</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>CV deaths</td>
<td>-/191</td>
<td>-/179</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>MI</td>
<td>-/191</td>
<td>-/179</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>all hypoglycemia</td>
<td>1/191</td>
<td>1/179</td>
<td>0.94</td>
<td>[0.06; 15.10]</td>
</tr>
<tr>
<td>Adverse events leading to treatment discontinuation</td>
<td>-/191</td>
<td>-/179</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>
5 References